<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский онкологический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1028-9984</issn><issn publication-format="electronic">2412-9119</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">40405</article-id><article-id pub-id-type="doi">10.18821/1028-9984-2017-22-3-131-135</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">ANALYSIS OF THE INTERRELATION OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR WITH PITUITARY ADENOMAS COMPLICATED BY PITUITARY APOPLEXY</article-title><trans-title-group xml:lang="ru"><trans-title>АНАЛИЗ ВЗАИМОСВЯЗИ ФАКТОРА РОСТА ЭНДОТЕЛИЯ СОСУДОВ С АДЕНОМАМИ ГИПОФИЗА, ОСЛОЖНЕННЫМИ ПИТУИТАРНОЙ АПОПЛЕКСИЕЙ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Makhkamov</surname><given-names>K. E</given-names></name><name xml:lang="ru"><surname>Махкамов</surname><given-names>К. Э</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Azizov</surname><given-names>Miralib M.</given-names></name><name xml:lang="ru"><surname>Азизов</surname><given-names>Миралим Мирабидович</given-names></name></name-alternatives><bio xml:lang="en"><p>MD, Senior Researches of the Department of the Neurosurgery, Tashkent, 100115, Republic of Uzbekistan</p></bio><bio xml:lang="ru"><p>старший научный сотрудник отдела нейрохирургии</p></bio><email>alimazizov1979@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vervekina</surname><given-names>T. A</given-names></name><name xml:lang="ru"><surname>Вервекина</surname><given-names>Т. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nishonov</surname><given-names>D. A</given-names></name><name xml:lang="ru"><surname>Нишонов</surname><given-names>Д. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Republican Research Centre of Emergency Medicine</institution></aff><aff><institution xml:lang="ru">Республиканский научный центр экстренной медицинской помощи Министерства здравоохранения Республики Узбекистан</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-06-15" publication-format="electronic"><day>15</day><month>06</month><year>2017</year></pub-date><volume>22</volume><issue>3</issue><issue-title xml:lang="en">VOL 22, NO3 (2017)</issue-title><issue-title xml:lang="ru">ТОМ 22, №3 (2017)</issue-title><fpage>131</fpage><lpage>135</lpage><history><date date-type="received" iso-8601-date="2020-07-22"><day>22</day><month>07</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, ООО "Эко-Вектор"</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">ООО "Эко-Вектор"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://rjonco.com/1028-9984/article/view/40405">https://rjonco.com/1028-9984/article/view/40405</self-uri><abstract xml:lang="en"><p>Aim. Despite the fact that the pituitary adenoma is a relatively benign tumor, sometimes the course of the disease is complicated by intramedullary hemorrhage. In the world literature there are single data on the molecular mechanism of hemorrhage in the adenomas of the pituitary gland. Vascular endothelial growth factor (VEGF) plays an important role in angiogenesis and permeability of the endothelium in various brain tumors. There was made an analysis of the relationship between pituitary apoplexy and VEGF expression in pituitary adenomas. Material and methods. Immunohistochemical investigation of the level of expression of the molecular-biological marker - VEGF was performed with the use of monoclonal antibodies with the method of semiquantitative analysis in 30 pituitary adenoma patients. In the clinical study data about the age, gender, hormonal activity and X-ray study were studied. There was executed a statistical analysis of the relationship between clinical diagnostic data and VEGF expression. Results. Hormonal active tumors were detected in 12 (40%) cases, intratumoral hemorrhage - in 16 (53.3%), adenomas with cystic component - in 7 (23.3%) and invasion of cavernous sinus - in 22 (73.3%) of cases. Expression of VEGF was observed in 11 cases (36.6%). Based on the analysis the expression of VEGF was found to be closely related to pituitary apoplexy (PA) in pituitary adenomas (p &lt; 0.001). However, there was no statistically significant relationship between VEGF and age, sex, tumor size, hormonal activity, cystic component presence, invasive tumor growth (p &gt; 0.05). Conclusion. It was found that immunohistochemical examination of the level of expression of a molecular biological marker VEGF can be used in the evaluation of the prognosis of the disease or the identification of a risk group with a high probability of the development of pituitary apoplexy and recurrence of tumor growth.</p></abstract><trans-abstract xml:lang="ru"><p>Цель. Несмотря на то что гипофизарная аденома - относительно доброкачественная опухоль, иногда течение заболевания осложняется интратуморальным кровоизлиянием. В мировой литературе имеются единичные данные о молекулярном механизме кровоизлияния в аденомах гипофиза. Фактор роста эндотелия сосудов (VEGF) играет важную роль в ангиогенезе и проницаемости эндотелия в различных опухолях головного мозга. Проведен анализ взаимосвязи между питуитарной апоплексией и экспрессией VEGF при аденомах гипофиза. Материал и методы. Иммуногистохимическое исследование уровня экспрессии молекулярно-биологического маркёра VEGF проведено с использованием моноклональных антител методом полуколичественного анализа у 30 больных с аденомой гипофиза. При клиническом исследовании изучены возрастные данные, пол, гормональная активность и данные рентгенологического исследования. Проведен статистический анализ взаимосвязи между клинико-диагностическими данными и экспрессией VEGF. Результаты. Гормонально активные опухоли выявлены в 12 (40%) случаях, интратуморальное кровоизлияние в 16 (53,3%), аденомы с кистозным компонентом в 7 (23,3%) и инвазия в кавернозный синус - в 22 (73,3%) случаях. Экспрессия VEGF наблюдалась в 11 случаях (36,6%). На основании проведенного анализа выявлено, что выраженность экспрессии VEGF тесно взаимосвязана с питуитарной апоплексией (ПА) при аденомах гипофиза (p &lt; 0,001). Однако статистической достоверной взаимосвязи между VEGF и возрастом, полом, размером опухоли, гормональной активностью, наличием кистозного компонента, инвазивным ростом опухоли не выявлено (p &gt; 0,05). Заключение. Выявлено, что иммуногистохимическое исследование уровня экспрессии молекулярно-биологического маркера VEGF может быть использовано в оценке прогноза заболевания или выделении группы риска с высокой степенью вероятности развития питуитарной апоплексии и рецидива опухолевого роста.</p></trans-abstract><kwd-group xml:lang="en"><kwd>angiogenesis</kwd><kwd>pituitary apoplexy</kwd><kwd>adenoma of the pituitary gland</kwd><kwd>vascular endothelial growth factor</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ангиогенез</kwd><kwd>питуитарная апоплексия</kwd><kwd>аденома гипофиза</kwd><kwd>фактор роста эндотелия сосудов</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Бабиченко И.И., Ковязин В.А. Новые методы иммуногистохимической диагностики опухолевого роста: Учебное пособие. М.: РУДН, 2008.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res. Treat. 1995; 36(2): 127-37.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Kurihara N., Takahashi S., Higano S., Ikeda H., Mugikura S., Singh L.N. et al. Hemorrhage in pituitary adenoma: correlation of MR imaging with operative findings. Eur. Radiol. 1998; 8: 971-6.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Connolly D.T. Vascular permeability factor a unique regulator of blood vessel function. J. Cell Biochem. 1991; 47: 219-23.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Yamada S., Takada K. Angiogenesis in pituitary adenomas. Microsc. Res. Tech. 2003; 60: 236-43.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ke L.D., Shi Y.X., Yung W.K. VEGF, VEGF over expression enhances tumorigenicity in U251 MG but not in NG-1 glioma cells. Cancer Res. 2002; 62: 1854-61.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Холова Д.Ш., Халимова З.Ю., Урманова Ю.М., Алиева Д.А., Алимухамедова Г.О. Состояние показателей процессов апоптоза и ангиогенеза у больных с неактивными аденомами гипофиза. Международный эндокринологический журнал. 2015; [6(70)]: 28-9.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Mendiola M., Barriuso J., Redondo A. et al. Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma. PLoS One. 2008; 3: 4051.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Jung S., Moon K.S., Jung T.Y., Kim I.Y., Lee Y.H., Rhu H.H. et al. Possible pathophysiological role of vascular endothelial growth factor(VEGF) and matrix metalloproteinase (MMPs) in metastatic brain tumor associated intracerebral hemorrhage. J. Neurooncol. 2006; 76: 257-63.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Arita K., Kurisu K., Tominaga A., Sugiyama K., Eguchi K., Hama S. et al. Relationship between intratumoral hemorrhage and over expression of vascular endothelial growth factor(VEGF) in pituitary adenoma. Hiroshima J. Med.Sci. 2004; 53: 23-7.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Fukui S., Otani N., Nawashiro H., Yano A., Nomura N., Tokumaru A.M. et al. The association of the expression of vascular endothelial growth factor with the cystic component and haemorrhage in pituitary adenoma. J. Clin. Neurosci. 2003; 10: 320-4.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999; 13: 9-22.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Карамышева А.Ф. Механизмы ангиогенеза. Биохимия. 2008; 73(7): 935-48.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Niveiro M., Aranda F.I., Peiro G., Alenda C., Pico A. Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas. Hum. Pathol. 2005; 36: 1090-5.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Adams J., Carder P.J., Downey S. et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 2000; 60(11): 2898-905.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Kim J.H., Chung Y.G., Lee H.K., Lee K.C., Suh J.K.: Evaluation of cerebrospinal fluid vascular endothelial growth factor for the brain tumor. J. Korean Neurosurg. Soc. 2003; 33: 121-5.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Cheng S.Y., Nagane M., Huang H.S., Cavenee W.K. Intracerebral tumor-associated hemorrhage caused by over expression of the vascular endothelial growth factor isoforms VEGF. Proc Natl. Acad. Sci. USA. 1997; 94: 12081-7.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>George L. Kumar, Lars Rudbeck. Иммуногистохимические методы: руководство. DAKO / Пер. с англ. под ред. Г.А. Франка, П.Г. Малькова. М., 2011.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Knosp E., Steiner E., Kitz K., Matula C.: Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 1993; 33: 610-8.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Biroccio A., Candiloro A., Mottolese M. et al. Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line. FASEB J. 2000; 14(5): 652-60.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Esser S., Wolburg K., Wolberg H., Breier G., Kurzchalia T., Risau W. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J. Cell Biol. 1998: 140(6): 947-59.</mixed-citation></ref></ref-list></back></article>
